Molecular Mechanism of Ganglion Cell Death in Glaucoma
About the Research Project
Program
Award Type
Standard
Award Amount
$49,408
Active Dates
April 01, 1999 - March 31, 2001
Grant ID
G1999007
Summary
Susceptibility to glaucoma may be governed by multiple genes affecting different parts of the eye, for example, genes affecting intraocular pressure in the anterior part of the eye. However, damage to the eye in the form of neuronal cell death is the critical event leading to blindness, and Dr. Nickells’ long-range goal is to identify genes that contribute to the survival of ganglion cells under various conditions, including conditions that may mimic human glaucoma. To simplify the search for these genes, he proposes that strains of mice need to be developed that can be easily measured for changes in ganglion cell number. He is working to develop mice that express a marker gene that can be used to rapidly screen for the phenotype of ganglion cell variation. These mice can then be used for identifying the genes affecting ganglion cell survival.
Related Grants
National Glaucoma Research
From Resilience to Vulnerability: How Stress Accelerates Aging
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Dorota Skowronska-Krawczyk, PhD
Current Organization
University Of California, Irvine
From Resilience to Vulnerability: How Stress Accelerates Aging
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Dorota Skowronska-Krawczyk, PhD
Current Organization
University Of California, Irvine
National Glaucoma Research
Novel Mechanisms to Regulate Eye Pressure
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Colleen McDowell, PhD
Current Organization
University of Wisconsin-Madison
Novel Mechanisms to Regulate Eye Pressure
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Colleen McDowell, PhD
Current Organization
University of Wisconsin-Madison
National Glaucoma Research
Developing a New Glaucoma Treatment That Avoids Daily Drops
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Gavin Roddy, MD, PhD
Current Organization
Mayo Clinic, Rochester
Developing a New Glaucoma Treatment That Avoids Daily Drops
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Gavin Roddy, MD, PhD
Current Organization
Mayo Clinic, Rochester